Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 15/20 | 0.72 |
| ▸ | NPC1 | O15118 | 14/20 | 0.72 |
| ▸ | GFER | P55789 | 4/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.72 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 10/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.65 |
| ▸ | TP53 | P04637 | 7/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.65 |
| ▸ | RELA | Q04206 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | CASP3 | P42574 | 1/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247289 | 0.99 | RAB9A (0.74) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL31696797 | 0.88 | RAB9A (0.93) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL17199136 | 0.87 | NPC1 (0.74) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL30296348 | 0.86 | RAB9A (0.96) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL2488592 | 0.86 | RAB9A (0.96) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL1852701 | 0.85 | RAB9A (1.00) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL29404722 | 0.85 | RAB9A (1.00) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL5376393 | 0.84 | RAB9A (1.00) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL2244350 | 0.83 | NPC1 (0.65) | RAB9ANPC1GFERRXFP1PIK3CB | |
| SCHEMBL25026542 | 0.83 | HDAC3 (0.60) | RAB9ANPC1GFERRXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447054-B2 | Anticancer supplement agent including benzo[D]oxazol derivative as effective ingredient | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2016-09-20 | — | — | US | claimed |
| US-20150197498-A1 | ANTICANCER SUPPLEMENT AGENT INCLUDING BENZO[D]OXAZOL DERIVATIVE AS EFFECTIVE INGREDIENT | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2015-07-16 | — | — | US | claimed |
| US-9447054-B2 | Anticancer supplement agent including benzo[D]oxazol derivative as effective ingredient | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2016-09-20 | — | — | US | disclosed |
| US-9447054-B2 | Anticancer supplement agent including benzo[D]oxazol derivative as effective ingredient | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2016-09-20 | — | — | US | disclosed |
| US-9447054-B2 | Anticancer supplement agent including benzo[D]oxazol derivative as effective ingredient | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2016-09-20 | — | — | US | disclosed |
| US-20150197498-A1 | ANTICANCER SUPPLEMENT AGENT INCLUDING BENZO[D]OXAZOL DERIVATIVE AS EFFECTIVE INGREDIENT | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2015-07-16 | — | — | US | disclosed |
| US-20150197498-A1 | ANTICANCER SUPPLEMENT AGENT INCLUDING BENZO[D]OXAZOL DERIVATIVE AS EFFECTIVE INGREDIENT | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2015-07-16 | — | — | US | disclosed |
| US-20150197498-A1 | ANTICANCER SUPPLEMENT AGENT INCLUDING BENZO[D]OXAZOL DERIVATIVE AS EFFECTIVE INGREDIENT | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197498-A1 | ANTICANCER SUPPLEMENT AGENT INCLUDING BENZO[D]OXAZOL DERIVATIVE AS EFFECTIVE INGREDIENT | NFE2L2, KEAP1, OXA1L | RAB9A 3858/4885NPC1 3193/4885GFER 1479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.